Abstract |
Phosphorothioate oligonucleotides which contain 35S at each internucleoside linkage have been prepared and employed to evaluate the in vivo pharmacokinetics in mice, rats and rabbits. A single administration of a 27-mer complementary to the rev gene of HIV into adult male rats by either the intravenous or intraperitoneal route reveals a biphasic plasma elimination. An initial half-life of 15-25 min represents distribution out of the plasma compartment and a second half-life of 20-40 h represents elimination from the body. The second half-life is significantly longer than a variety of nucleic acids such as poly-IC and Ampligen and suggests therapy with phosphorothioate oligonucleotides should be possible and practical. Repeated daily injections of the 27-mer provides steady-state concentrations in 6-9 days, confirming the estimated long half-life from single injection studies. Finally, chronic treatment studies indicate that the phosphorothioate oligonucleotides are relatively non-toxic. Hence, pharmacokinetic considerations are not likely to be limiting factors in anti- cancer drug design with phosphorothioate oligonucleotides.
|
Authors | P Iversen |
Journal | Anti-cancer drug design
(Anticancer Drug Des)
Vol. 6
Issue 6
Pg. 531-8
(Dec 1991)
ISSN: 0266-9536 [Print] United States |
PMID | 1772568
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
|
Chemical References |
- Oligonucleotides
- Thionucleotides
|
Topics |
- Animals
- Base Sequence
- Humans
- Molecular Sequence Data
- Oligonucleotides
(administration & dosage, pharmacokinetics)
- Thionucleotides
(administration & dosage, pharmacokinetics)
|